Business

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

The Economic Times · 24 August 2026 at 6:20 am

Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations.

The company holds a global leadership position in corticosteroid and steroidal-hormone APIs.

Its revenue primarily comes from international markets, with Europe being a significant contributor.

Financials show steady revenue and EBITDA growth over recent years.

Investors with a high-risk appetite may consider this long-term opportunity.

Read the full article on The Economic Times ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on economictimes.indiatimes.com — the content belongs to The Economic Times.

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

More from The Economic Times

Paul Black’s 3 thumb rules for identifying great wealth creators

Silver rebounds from correction: Can the recovery gain momentum?

Bitcoin falls below $78,000 as crypto market faces correction after Warsh’s Jackson Hole comments

Reliance JIO IPO: 7 risk factors investors should know as firm gets Sebi nod for Rs 37,000-crore offer

More in Business

Money rules changing from September 1: ITR deadlines, KYC updates and cost revisions you need to know

China offers emergency aid to flood-hit Nepal as death toll crosses 650

Demand for education loans surges to 86.5% in Tier II, III cities, financing trends shifting, finds Kuhoo Finance report

Sonia Gandhi electoral roll case: Delhi court defers plea order to Sept 21

Dussehra bonus: Central govt employees demand 3x jump in ₹7,000 payment ceiling

Bank holidays in September: SBI, HDFC, other lenders to be closed for 14 days— check RBI calendar, unions' strike date